Category: Breaking News

(Reuters) – United Airlines and Delta Air Lines on Thursday said they had each canceled dozens of Christmas Eve flights, as the spreading COVID-19 Omicron variant takes a toll on its flight crews and other workers. Chicago-based United canceled 120 flights for Friday, while Atlanta-based Delta said it has canceled about 90. Both said they were working to contact passengers so they would not be stranded at airports. “The nationwide spike in Omicron cases this week has had a direct impact on our flight crews and the people who run our operation. As a result, we’ve unfortunately had to cancel some flights and are notifying impacted customers in advance of them coming to the airport,” United said. Delta said it has “exhausted all options and resources — including rerouting and substitutions of aircraft and crews to cover scheduled flying — before canceling around 90 flights for Friday.” Delta cited potential inclement weather and the impact of the Omicron variant for the cancellations. On Tuesday, Delta Chief Executive Ed Bastian asked the head of the U.S. Centers for Disease Control and Prevention (CDC) to shrink quarantine guidelines for fully vaccinated individuals who experience breakthrough COVID-19 infections, citing the impact on the carrier’s workforce. Bastian asked that the isolation period be cut to five days from the current 10. That request was echoed both by Airlines for America, a trade group representing major cargo and passenger carriers, which wrote to the CDC on Thursday, and by JetBlue on Wednesday. The CDC released updated quarantine guidance for healthcare workers on Thursday, cutting the isolation time to seven days for workers who test positive for COVID-19 but are asymptomatic, providing they test negative.

* European, Asian shares gain on Omicron severity data

* Safe-haven bonds less favoured

* U.S. consumer confidence grows

By Alun John and Lawrence White

HONG KONG/LONDON, Dec 23 (Reuters) – Global shares extended a recent rally on Thursday while safe-haven bonds and currencies eased as markets welcomed signs that the Omicron variant of COVID-19 might be less severe than feared, as well as robust U.S. economic data. The STOXX index of Europe’s 600 largest shares rose 0.3%, following earlier gains in Asia. Japan’s Nikkei gained 0.57% and MSCI’s broadest index of Asia-Pacific shares outside Japan rose 0.8%. It put stock markets on course for a third successive day of gains as they recovered from a jolt on Monday when worries about the new coronavirus variant pushed investors to safe-haven assets like the greenback. “The recent health data from the UK and other places around the world indicate that the worst case is unlikely: even though (Omicron) transmission rates are reportedly higher, this variant seems less virulent and less prone to cause serious illnesses or death,” said David Chao, global market strategist Asia Pacific at Invesco. The risk of needing to stay in hospital for patients with the Omicron variant of COVID-19 is 40-45% lower than for patients with the Delta variant, according to research by London’s Imperial College published on Wednesday. European government bond yields continued to tick up as the trickle of risk sentiment flowing back into the market reduced the need for safe-haven debt. Germany’s 10-year Bund yields hit -0.284%, their highest since late November.

Strained hospitals bracing for a COVID-19 surge caused by the quickly spreading Omicron variant could face another grim possibility: preliminary experiments suggest that most of the antibody treatments for the disease are powerless against Omicron^1,2,3,4. Doctors use artificial versions of natural antibodies to stave off severe COVID-19 in high-risk people who are infected with the coronavirus. But a slew of publications posted on preprint servers report laboratory evidence that Omicron is totally or partially resistant to all currently available treatments based on these monoclonal antibodies. The publications have not yet been peer reviewed, but some of the companies that manufacture antibody therapies already concede that their products have lower potency against Omicron than against other variants. The preprints report that only two antibodies show strong evidence of retaining some ability to thwart the variant: sotrovimab, developed by Vir Biotechnology in San Francisco, California, and GSK, headquartered in London; and DXP-604, which is undergoing clinical trials in China and was developed by BeiGene and Singlomics, both based in Beijing.
Continue reading “Hospitals have run out of the only antibody treatment that works against people infected by the Omicron mutation”